Enlivex Ltd. (NASDAQ:ENLV)

IL · Delayed Price · Currency is USD

Also listed: ENLV.TAHealthcare · Biotechnology

Full ChartAlerts Compare

1.78-0.76 (-29.92%)

Market cap

$30.0M

Insider Score

Not scored

Health Score

54 Fair

Analyst consensus

Moderate Buy

Listed since

Jul 31, 2014

Website

enlivex.com

Market Cap	29.96M-99.3%
Revenue (ttm)	0
Net Income	4.11B+31455.8%
EPS	244.00+6092.4%
Shares Out	16.83M
PE Ratio	0.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,872
Open	1.75
Previous Close	2.54
Day's Range	1.75 - 2.47
52-Week Range	1.73 - 434.40
Beta	1.41
Analysts	Buy
Price Target	15.00(+742.70%)
Earnings Date	Nov 13, 2026

Full Chart

Alerts Compare

Insider Score

––Not scored

ENLV Insider Score

No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.

See stocks that are scored

About ENLV

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Address

14 Einstein Street, Ness Ziona, TA, 7403618, IL

Market Cap

30 million

Employees

Industrial Classification

Biotechnology

Analyst consensus

Moderate Buy

1 Buy0 Hold0 Sell

1 firm rating ENLV in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score

Fair

From ENLV’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Latest investor presentation

Next catalysts

Nov 13, 2026Earnings report

Ask Barron about ENLV

1 Day

-29.92%

5 Days

-35.74%

1 Month

-77.86%

6 Months

-99.10%

1 Year

-99.29%

$ENLV stock is featured in our Insider Trades datasets.

→ All Stock Lists

Whale Activity →

Recently reported changes in ENLV holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ENLV's directors and management

No SEC Form 4 activity for ENLV in the last 5 quarters.

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ENLV Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ENLV patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ENLV from public contracts

Source: USAspending.gov

ENLV Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for ENLV yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from ENLV’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity

No data yet

—

Analyst Ratings

100% of score

News & Sentiment

No data yet

—

Recent Insider Activity

No Form 4 filings in the last 90 days.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.